0001610717-24-000031.txt : 20240119 0001610717-24-000031.hdr.sgml : 20240119 20240119203727 ACCESSION NUMBER: 0001610717-24-000031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240118 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chu Yu-Waye CENTRAL INDEX KEY: 0001854586 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 24546893 MAIL ADDRESS: STREET 1: FATE THERAPEUTICS, INC. STREET 2: 3535 GENERAL ATOMICS COURT STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273521219 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-01-18 0001501989 CytomX Therapeutics, Inc. CTMX 0001854586 Chu Yu-Waye C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 SOUTH SAN FRANCISCO CA 94080 true Chief Medical Officer false Common Stock 2024-01-18 4 A 0 26250 0 A 26250 D Stock Option (Right to Buy) 1.68 2024-01-18 4 A 0 122500 0 A 2034-01-17 Common Stock 122500 122500 D Performance Stock Units (PSUs) 2024-01-18 4 A 0 75000 0 A Common Stock 75000 75000 D Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date. Includes 26,250 RSUs. 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. /s/ Lloyd Rowland, as Attorney-in-Fact for Yu-Waye Chu 2024-01-22